Clinical trial
Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese…
NCT00356447 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00356447 |
|---|---|
| Title | Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms. |
| Official title | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Investigating the Efficacy and Tolerability of Angeliq® (Drospirenone 2mg and Estradiol 1mg) in Postmenopausal Chinese Women With Vasomotor Symptoms Over Four 28-day Treatment Cycles. |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Vasomotor Symptoms |
| Intervention type | Drug |
| Interventions | Estradiol/DRSP (Angeliq, BAY86-4891), Placebo |
| Enrollment | 249 |
| Start date | May 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Jul 26, 2006 |
| Last update posted | Oct 1, 2014 |
| Countries | China |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: